![Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker](https://cdn.cancerletter.com/media/2024/01/02050657/40-37-Avastin-Herceptin-Rituxan.jpg)
![Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker](https://cdn.cancerletter.com/media/2024/01/02050657/40-37-Avastin-Herceptin-Rituxan.jpg)
Cover Story
A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company's top-selling infused cancer drugs.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence